This report analyzes the worldwide markets for Bulk Paclitaxel in kilograms and US$ Million. The report provides separate comprehensive analytics for the US, and Rest of World. Annual forecasts are provided for the period of 2000 through 2015. The report profiles 35 companies including many key and niche players worldwide such as Abraxis BioScience, Inc., Bioxel Pharma, Inc., Bristol-Myers Squibb Co., Hospira, Inc., Indena S.p.A., OncoGenex Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Xechem International Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

BULK PACLITAXEL									MCP-1208
A GLOBAL STRATEGIC BUSINESS REPORT


                                             CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-3
      Product Definitions and Scope of Study                            I-3


 II. EXECUTIVE SUMMARY

  1. Industry Overview                                                  II-1
      Paclitaxel - Leading from the Front                               II-1
      US Market - Magnificently Outdistancing Others                    II-1
      Cancer Blockbusters - Facing the Brunt                            II-1
      A Sunrise Opportunity                                             II-1
       BMS' Reign Comes to an End                                       II-2
      Exploring New Avenues                                             II-2
      Falling Prices - Boon for The Customers, Bane for The Companies   II-2
      All the Strangle for Peanuts?                                     II-3
      Factors Affecting the Market                                      II-3
      Paclitaxel Versus Abraxane                                        II-3

  2. Outlook                                                            II-5
      Bulk Paclitaxel - Great Future Ahead                              II-5
      Competitive Scenario                                              II-5
      Cancer Generics - A Time for Optimism                             II-5
      The US Piazza                                                     II-6

  3. Product Overview                                                   II-7
      Chemical Properties                                               II-7
      Sourcing                                                          II-7
       From Natural Sources                                             II-8
        Yew Trees                                                       II-8
       From Semi-Synthesis Process                                      II-8
      Mechanism of Action                                               II-8
      History of Paclitaxel and its Discovery as an Anti-Cancer Agent   II-9
      China Wins Laurels for Supply of Natural Paclitaxel               II-10
      Hazelnut Trees Emerge as the Alternate Source of Paclitaxel       II-10
      Taxol - The Uncrowned Leader                                      II-11
      Paclitaxel - Concerns                                             II-11
      Abraxane and Tocosol: Set to Ride the Market Duel?                II-11
      Many Faces (Phases) of Paclitaxel - The Variants                  II-12
      Taxotere - A Potential Competitor to Paclitaxel                   II-12

  4. Research and Development                                           II-13
      Angiotech Unfurls New Dimensions for Paclitaxel                   II-13
      Clinical Research Favors Paclitaxel for Breast Cancer Treatment   II-13
      American BioScience' Nab Technology Unveils Higher Tissue
       Penetration Potential                                            II-13
      Naturol Develops Unique Extraction Technology for Producing
       Paclitaxel from Canadian Yew                                     II-14
      Ivax Corp.'s Xorane Revolutionizes the Delivery of Paclitaxel     II-14

  5. Product Launches/Introductions                                     II-15
      Dabur Launches Cancer Drug.                                       II-15
      Dabur Introduces Nanoxel.                                         II-15
      Nippon Introduces Paclitaxel Injection NK.                        II-15

  6. Recent Industry Activity                                           II-16
      Sonus to Merge with OncoGenex                                     II-16
      Acusphere Signs Licensing Deal with Cephalon                      II-16
      Sonus Terminates TOCOSOL Paclitaxel Development Program           II-16
      Eagle Pharmaceuticals to Develop and Market Tocosol Paclitaxel    II-16
      Pliva Lachema Receives ANDA for Paclitaxel Injection              II-16
      Cell Therapeutics Receives EMEA Acceptance                        II-17
      Abraxis Wins Approval for ABRAXANE in Korea                       II-17
      Boston Scientific Obtains Approval for TAXUS Liberte from
       Health Canada .                                                  II-17
      Cell Therapeutics Renames Xyotax as Opaxio                        II-17
      Hospira Takes Over Mayne Pharma                                   II-17
      Protherics to Acquire MacroMed                                    II-17
      Abraxis Acquires Arizona Production Facility                      II-18
      Indena Inks Worldwide License Agreement with Spectrum Pharma      II-18
      Bioxel Bags Major Paclitaxel Order                                II-18
      Bioxel Enters into Supply Agreement                               II-18
      Bioxel Bags Paclitaxel Supply Contract                            II-19
      Indena Establishes New Plant to Produce Synthetic Paclitaxel      II-19
      Abraxis Selects Korean Green Cross to Market ABRAXANE             II-19
      Abraxis Grants License to Biocon for Marketing ABRAXANE           II-19
      Bioxel Registers Docetaxel with US FDA                            II-19
      Bayer Quashes TOCOSOL Paclitaxel License with Sonus               II-20
      Abraxis' ABRAXANE Convinces European CHMP                         II-20
      Abraxis Receives Approval for ABRAXANE in Australia               II-20
      Eurocor Receives CE Mark                                          II-20
      SuperGen Divests Certain Drugs to Intas                           II-20
      Abraxis Plans Separation of Oncology Business                     II-20
      Teva Acquires IVAX                                                II-21
      Mayne to Acquire Nipent and SurfaceSafe Product  Rights in
       North America                                                    II-21
      Athersys Expands Research Collaboration with  Bristol-Myers
       Squibb                                                           II-21
      American Pharmaceutical Partners and American  BioScience
       Combine to Create Abraxis BioScience                             II-22
      Bioxel Increases its Presence in Europe                           II-22
      Xechem Resolves Paclitaxel Antitrust Lawsuit  with Bristol-
       Myers Squibb                                                     II-22
      Angiotech Acquires American Medical Instruments                   II-22
      Paxis Signs Supply Agreement for Europe and  the United States    II-22
      Angiotech to Take Over Quill Medical                              II-22
      Bioxel and Cook Enters Supply Agreement for Paclitaxel            II-23
      Angiotech Acquires Lifespan Vascular Graft Business               II-23
      Bristol-Myers Extends Agreement with Ambit                        II-23
      Angiotech Takes Over Afmedica                                     II-23
      Bristol-Myers Squibb Gets European Approval for Paclitaxel        II-23
      Angiotech Signs Exclusive License Agreement with  CABG Medical    II-24
      Conor Medsystems Acquires the Assets of  Phytogen Life Sciences   II-24
      Sonus Pharmaceuticals and Schering Sign Licensing Agreement.      II-24
      Sonus' Tocosol Wins FDA's ODD                                     II-24
      ABI's Abraxane Wins FDA Approval                                  II-25
      SuperGen's Paclitaxel Injection Accorded ANDA Status from the
       USFDA                                                            II-25
      Ivax Signs Agreement with Mayne                                   II-25
      Integrated Bio Pharma Acquires Hauser CRO                         II-25
      Mayne Gearing up to Fight it Alone with Proprietary Paclitaxel    II-25
      Bioxel Inks a Paclitaxel Supply Deal with CTI                     II-25
      DFB Pharmaceuticals Takes Over Phyton                             II-25
      NaPro Divests Paclitaxel Business to Faulding                     II-26
      Bioxel-Aerojet's Large-Scale Paclitaxel Purification Process
       Gets FDA's Nod                                                   II-26
      Ivax Earns Expanded Approval for Paxene from the European
       Commission                                                       II-26
      Sonus Obtains Third Patent for the Composition of Tocosol
       Paclitaxel                                                       II-26
      Bioxel Forays into the European Market                            II-26
      Xechem Pockets Additional Patents for Second Generation
       Paclitaxel                                                       II-27
      Dabur Pharma Initiates Phase IIb Trial for Nanoparticle
       Delivery Systems                                                 II-27
      Acusphere Inc. Completes Phase 1 Trial for AI-850                 II-27
      Tisorex Changes Name to Paxis Pharmaceuticals                     II-27

  7. Focus on Select Global Players                                     II-28
      Abraxis BioScience, Inc. (USA)                                    II-28
      Bioxel Pharma Inc. (Canada)                                       II-28
      Bristol-Myers Squibb Co. (USA)                                    II-28
      Hospira, Inc. (USA) .                                             II-28
      Indena S.p.A. (Italy)                                             II-29
      OncoGenex Pharmaceuticals, Inc. (USA).                            II-29
      Teva Pharmaceuticals USA, Inc. (USA) .                            II-29
      Xechem International Inc. (USA)                                   II-30

  8. Global Market Perspective                                          II-31
      Table 1: World Recent Past, Current & Future  Analysis for
      Bulk Paclitaxel by Geographic Region -  US and Rest of World
      Markets Independently  Analyzed with Annual Sales in Kilograms
      for  Years 2000 through 2010 (includes  corresponding
      Graph/Chart)                                                      II-31

      Table 2: World Long-term Projections for Bulk Paclitaxel by
      Geographic Region - US and Rest of World Markets Independently
      Analyzed with Annual Sales in Kilograms for Years 2011 through
      2015 (includes corresponding Graph/Chart)                         II-32

      Table 3: World Recent Past, Current & Future Analysis for Bulk
      Paclitaxel by Geographic Region - US and Rest of World Markets
      Independently Analyzed with Annual Sales in US$ Million for
      Years 2000 through 2010 (includes corresponding Graph/Chart)      II-33

      Table 4: World Long-term Projections for Bulk Paclitaxel by
      Geographic Region - US and Rest of World Markets Independently
      Analyzed with Annual Sales in US$ Million for Years 2011
      through 2015 (includes corresponding Graph/Chart)                 II-34

      Table 5: World 10-Year Perspective for Bulk Paclitaxel by
      Geographic Region - Percentage Breakdown by Volume Sales for
      US and Rest of World Markets for Years 2003, 2008, & 2012         II-35

      Table 6: World 10-Year Perspective for Bulk Paclitaxel by
      Geographic Region - Percentage Breakdown by Dollar Sales for
      US and Rest of World Markets for Years 2003, 2008, & 2012         II-35


III. MARKET

  1. The United States                                                  III-1
      A.Market Analysis                                                 III-1
        Current and Future Analysis                                     III-1
        Rising Demand for Paclitaxel                                    III-1
         Alarming Growth of Breast Cancer                               III-1
         Clinical Research Favors Paclitaxel for  Breast Cancer
          Treatment                                                     III-1
         Paclitaxel - An Important Element                              III-2
        Corporate Talk                                                  III-2
        Drug-Eluting Stents - Marching Ahead                            III-2
        Strategic Corporate Developments                                III-2
        Key Players                                                     III-7
      B.Market Analytics                                                III-10
        Table 7: US Recent Past, Current & Future Analysis for Bulk
        Paclitaxel Market with Annual Sales in Kilograms for Years
        2000 through 2010 (includes corresponding Graph/Chart)          III-10

        Table 8: US Long-term Projections for Bulk  Paclitaxel
        Market with Annual Sales in Kilograms  for Years 2011
        through 2015.(includes  corresponding Graph/Chart)              III-10

        Table 9: US Recent Past, Current & Future Analysis  for Bulk
        Paclitaxel Market with Annual Sales  in US$ Million for
        Years 2000 through 2010  (includes corresponding
        Graph/Chart)                                                    III-11

        Table 10: US Long-term Projections for  Bulk Paclitaxel
        Market with Annual Sales  in US$ Million for Years 2011
        through 2015  (includes corresponding Graph/Chart)              III-11

  2. Rest of World                                                      III-12
      A.Market Analysis                                                 III-12
        Current and Future Analysis                                     III-12
        Europe.                                                         III-12
         European Market Overview                                       III-12
         European Market Battling Cost-Containment Woes                 III-12
          Efforts to Improve the Scenario and their Effect on
           Paclitaxel Market                                            III-13
        China.                                                          III-13
         Chinese Government Strategizing to Save  Paclitaxel Reserves   III-13
        Product Launches/Developments.                                  III-13
        Strategic Corporate Development                                 III-14
        Key Players                                                     III-20
      B.Market Analytics                                                III-22
        Table 11: Rest of World Recent Past, Current & Future
        Analysis for Bulk Paclitaxel Market with Annual Sales  in
        Kilograms for Years 2000 through 2010 (includes
        corresponding Graph/Chart)                                      III-22

        Table 12: Rest of World Long-term  Projections for Bulk
        Paclitaxel with  Annual Sales in Kilograms for Years 2011
        through 2015 (includes corresponding  Graph/Chart)              III-22

        Table 13: Rest of World Recent Past,  Current & Future
        Analysis for Bulk  Paclitaxel Market with Annual Sales  in
        US$ Million for Years 2000 through  2010 (includes
        corresponding  Graph/Chart)                                     III-23

        Table 14: Rest of World Long-term  Projections for Bulk
        Paclitaxel Market  with Annual Sales in US$ Million for
        Years  2011 through 2015 (includes corresponding
        Graph/Chart).                                                   III-23


 IV. COMPETITIVE LANDSCAPE